Psoriasis is a chronic systemic inflammatory skin disease, which has been associated with an increased risk of numerous medical and psychiatric comorbidities, including suicidality. Suicidality, which can be divided into the categories of suicidal ideation, suicide attempt, and completed suicide, is highly prevalent in the psoriasis population, and multiple studies have been published on the subject of psoriasis and suicidal ideation and behavior (SIB), including two recent metaanalyses. However, the available literature is limited and inconsistent, and the association between the two remains incompletely understood. The present review aims to cohesively synthesize and summarize the available evidence, while making a clinically relevant distinction between the sub-categories of suicidality, by examining not only the epidemiology of the association but also the plausible molecular mechanisms and the potential influence of biologic therapies. Additionally, this review aims to critically examine and understand the potential contribution of depression in the psoriasis and suicidality relationship. This will allow us to better understand the complex and multi-faceted relationship between psoriasis and suicidality, to identify those who may be most at risk for SIB, to make evidence-based clinical decisions regarding treatment and management, and to more completely address the needs of psoriasis patients.
prevalence of suicidal ideation and suicide attempt is 14.3% and 8.7%, respectively (Nock et al., 2008; Xu et al., 2016) .
The relationship between dermatologic diseases and SIB has gained increasing attention in the literature. Recently, a number of studies have been published on the subject of psoriasis and suicidality.
However, the results are often inconsistent, and sometimes a clinically relevant distinction between suicidal ideation (SI), suicide attempt, and completed suicide is not performed or only limited aspects are assessed. Few studies examine the entirety of the psoriasis and suicidality relationship, which includes the epidemiology of the subcategories of suicidality, the molecular mechanisms, and the potential influence of biologic therapies. Thus, the aim of this article is to provide a complementary review, cohesively synthesize the available information, and describe various aspects of the association that have been seldom delineated. Additionally, this review aims to critically examine and understand the potential contribution of depression in the psoriasis and suicidality relationship and identify gaps in our understanding that can be addressed in future studies.
| METHODS
A literature search of the PubMed Database was conducted for published studies from 1970 to 2018 using search terms that included "psoriasis", "suicidality", and "suicid*". Original sources cited within articles were retrieved when necessary. English-language articles examining the association of psoriasis with various aspects of suicidality were identified (Table 1) (Abuabara et al., 2010; Chi et al., 2017; Dalgard et al., 2015; Egeberg et al., 2016; Friedman et al., 2006; Gupta et al., 1993; Gupta & Gupta, 1998; Kimball et al., 2012; Kimball et al., 2014; Krueger et al., 2001; Kurd et al., 2010; Lamb et al., 2017; Picardi et al., 2006; Pompili et al., 2016; Pompili et al., 2017; Rapp et al., 1997; Sanna et al., 2014; Sharma et al., 2001; Singh et al., 2017; Singhal et al., 2014; Svedbom et al., 2015; Wu et al., 2017; Zachariae et al., 2004) .
| PSORIASIS & SUICIDALITY

| Suicide prevalence and incidence
In patients with psoriasis, the incidence of suicidality has been reported at 0.9 per 1,000 person-years (vs. 0.7 per 1,000 person-years in the general population), and in the U.K. alone, there are approximately 350 new diagnoses of suicidality attributable to psoriasis each year (Kurd et al., 2010) . Among United States psoriasis patients, the prevalence of SI has been reported to be as high as 9.7% (vs. 4% in the general population) (Gupta et al., 1993; Piscopo, Lipari, Cooney, & Glasheen, 2016) . Similarly, in an Italian study, the prevalence of SI in psoriasis patients was found to be near 10% (Picardi et al., 2006) . However, in a multicenter study, which included 626 psoriasis patients from 13 European countries, the prevalence of SI was found to be substantially higher at 17.3% (vs. 8.3% in healthy controls), with 67.6% of suicidal individuals reporting that their SI was directly related to their psoriasis (Dalgard et al., 2015) . In another study of 113 Danish psoriasis patients, an even higher percentage (21.2%) reported thoughts about suicide (vs. 6.8% in individuals without the disease) (Zachariae et al., 2004) . Furthermore, there is a high prevalence of lifetime SI in psoriasis patients, with as many as 37.4% reporting a history of SI (vs. 16.7% in patients without psoriasis) (Pompili et al., 2016; Pompili et al., 2017) . Among psoriasis patients, the incidence of suicide attempt has been reported at 1.43 per 10,000 person-years (vs. 1.00 per 10,000
person-years in the general population) (Egeberg et al., 2016) . Psoriasis patients also have a high incidence of completed suicide, with an incidence rate of 2.03 per 10,000 person-years (vs. 1.64 per 10,000 groups, not significant for "Severe Psoriasis" group. e Described as "nonfatal self harm." f Difference only significant for "Past SI," not significant for "Current SI." *Final measure of effect or difference statistically significant (p < .05).
person-years in the general population) (Egeberg et al., 2016; Svedbom et al., 2015) . Patients with psoriasis suffer substantial psychiatric comorbidity, and the high incidence and prevalence of SIB observed in this population raises the question of whether psoriasis patients have an increased risk of suicidality compared to not only healthy individuals but also other dermatologic patients.
3.2 | Risk of suicidal ideation, suicide attempt, and completed suicide Several studies suggest a relationship between psoriasis and an increased risk of suicidality (Dalgard et al., 2015; Kurd et al., 2010; Singh et al., 2017; Zachariae et al., 2004) , with psoriasis having a stronger association with an increased risk than other dermatologic conditions (Gupta & Gupta, 1998; Picardi et al., 2006; Pompili et al., 2016; Pompili et al., 2017) . However, other studies, including a recent population-based cohort study of over 68,000 psoriasis patients, have not found a significant association (Abuabara et al., 2010; Egeberg et al., 2016; Kimball et al., 2012; Sanna et al., 2014; Svedbom et al., 2015; Wu et al., 2017) A few studies have investigated the composite outcome of "any suicidality," which includes a diagnosis of SI, suicide attempt, and/or completed suicide (Kurd et al., 2010; Wu et al., 2017) . In a populationbased cohort study of nearly 150,000 psoriasis patients by Kurd et al., patients with psoriasis were found to have a significantly increased risk of any suicidality compared to the general population (adjusted hazard ratio [HR] 1.44; 95% confidence interval [CI] 1.32-1.57) (Kurd et al., 2010) . However, another population-based cohort study of 36,214 psoriasis patients did not find a significantly increased risk (Wu et al., 2017) , and when the two studies were analyzed together in the recent meta-analysis by Chi et al., a significantly increased risk of any suicidality was not found in patients with psoriasis (pooled risk ratio [RR] 1.26; 95% CI 0.97-1.64) (Chi et al., 2017) .
Regarding SI, the recent meta-analysis by Singh et al., which reviewed eight articles of either case-control, cross-sectional, or cohort design, found that patients with psoriasis are more than twice as likely to have SI compared to patients without (pooled odds ratio
[OR] 2.05; 95% CI 1.54-2.74) (Singh et al., 2017) . These results, however, contrast with Chi et al.'s meta-analysis, which examined only population-based cohort studies (Chi et al., 2017) . In Chi et al.'s metaanalysis, two studies investigated the association between psoriasis and SI directly (Kimball et al., 2012; Xu et al., 2016) . Although a metaanalysis could not be performed due to the different age groups included in the studies, neither study found an increased risk of SI in psoriasis patients (Chi et al., 2017; Kimball et al., 2012; Wu et al., 2017) .
When evaluating the relationship between psoriasis and suicide attempt, Singh et al. found that patients with psoriasis are more likely to attempt suicide than controls (pooled OR 1.32; 95% CI 1.14-1.54) (Singh et al., 2017) . However, in the meta-analysis by Chi et al., which included three cohort studies examining the association between psoriasis and suicide attempt (Egeberg et al., 2016; Singhal et al., 2014; Xu et al., 2016) , a significantly increased risk of suicide attempt was not found in psoriasis patients (pooled RR 1.25; 95% CI 0.89-1.75) (Chi et al., 2017) .
In several studies investigating the most serious outcome of completed suicide, patients with psoriasis have been found to be more likely to complete suicide than patients without the disease (Singh et al., 2017) . In Singh et al.'s meta-analysis, the pooled OR of completed suicide in psoriasis patients was 1.20 (95% CI 1.04-1.39), demonstrating a significantly higher likelihood of completed suicide in psoriasis patients (Singh et al., 2017) . Nonetheless, similar to the findings in each of the other categories, neither of the two cohort studies employed in Chi et al.'s meta-analysis found a significant difference in the risk of completed suicide between people with and without psoriasis individually nor collectively (pooled RR 1.13; 95% CI 0.87-1.46) (Chi et al., 2017; Egeberg et al., 2016; Singhal et al., 2014) .
The significantly increased risk of SIB in psoriasis patients reported by Singh et al. may be attributed to the inclusion of casecontrol and cross-sectional studies in addition to cohort studies (Singh et al., 2017) . Additionally, although their article screening process was thorough, Singh et al. did not include the 2014 population-based cohort study by Singhal et al., which found an increased risk of nonfatal self-harm among the included 119,304 psoriasis patients (rate ratio 1.6; 95% CI 1.5-1.7) but no significantly increased risk of completed suicide compared to the reference cohort (Singhal et al., 2014 However, interpretation of their findings is limited by the heterogeneity and quality of the studies included. Therefore, additional prospective, controlled studies are necessary to further investigate this relationship.
| Risk factors
Given the presence of literature in support of the association between psoriasis and suicidality, it is essential for physicians to identify patients who may be most at risk for SIB. In the available literature, several risk factors for increased suicidality have been identified in psoriasis patients. These risk factors include young age (Egeberg et al., 2016; Krueger et al., 2001; Kurd et al., 2010; Rapp et al., 1997; Singh et al., 2017; Singhal et al., 2014) , concomitant psychiatric illness (Lamb et al., 2017; Picardi et al., 2006; Sanna et al., 2014) , and increased severity of disease (Egeberg et al., 2016; Gupta et al., 1993; Kurd et al., 2010; Rapp et al., 1997; Singh et al., 2017) .
| Age
Although psoriasis can occur at any age, in approximately 75% of cases the onset of disease is before age 40, and in over 50% of people, onset occurs before the age of 30 (Farber & Nall, 1974 
| Psychiatric comorbidity
Compared to healthy individuals, patients with psoriasis are almost 1.4-times more likely to experience depression (Kurd et al., 2010) . In the U.S., the prevalence of major depression among psoriasis patients is 16.5%, and even after adjusting for cardiovascular risk factors, a history of psoriasis is an independent risk factor for major depression (Cohen et al., 2016) . In a cross-sectional study examining the demographic, clinical, and psychosocial factors associated with SI among psoriasis patients, the presence of depression or another depressive disorder was the strongest predictor of SI (OR 12.8; 95% CI 6.3-26.1) (Picardi et al., 2006) . Additionally, in a cohort of U.K. psoriasis patients, the rate of suicidality was 10-times greater among those with comorbid depression compared with the overall group (35% vs. 3.5%, respectively) (Lamb et al., 2017). However, similarly to age, this association may be a function of the fact that psychiatric illnesses, including depression, are well-known risk factors for SIB and are strongly associated with an increased risk of suicidality not only in patients with psoriasis but also in general (Singhal et al., 2014 (Dalgard et al., 2015) . Therefore, although the mediatory effect of depression on the association between psoriasis and SIB remains unclear, psychiatric comorbidity should be considered when evaluating psoriasis patients' risk of suicidality.
| Disease severity
Psoriasis severity can also contribute to suicidality, as an increased severity of disease has been associated with greater impairment in health-related quality-of-life (HRQoL) (Singh et al., 2017) . Several studies have found that patients with more severe psoriasis are more likely to have SIB (Egeberg et al., 2016; Gupta et al., 1993; Kurd et al., 2010; Rapp et al., 1997) . When compared to patients with mild psoriasis, patients with severe disease, classified as having received systemic psoriasis therapy, have a significantly increased risk of self-harm and suicide attempt (age-and sex-adjusted IRR 2.04; 95% CI 1.21-3.44; p = .008) (Egeberg et al., 2016) . Although the link between disease severity and risk of suicidality is conflicting in other reports with some studies reporting no significant relationship (Chi et al., 2017; Wu et al., 2017) , the association still warrants special attention, as effective treatment can not only improve disease severity but also potentially decrease suicide-related mortality.
| Plausible biologic mechanisms
Although the association between psoriasis and suicidality may be have been found at increased levels in the plasma and central nervous system (CNS) of individuals with depression and suicidality (Lindqvist et al., 2009; Pandey et al., 2014) .
Among the various implicated cytokines, IL-6, IL-17, and TNF-α, which are all produced in high concentrations in psoriasis, have been specifically explored. Significantly elevated concentrations of IL-6, IL-17, and TNF-α have all been observed in the systemic circulation of patients with acute and refractory depression (Chen et al., 2011; Himmerich et al., 2008; Maes et al., 1997) . In a 2017 study by Nadeem et al., increased systemic and neuronal IL-17A expression was found to be concurrent with the development of depression-like symptoms in mice after the induction of psoriatic inflammation (Nadeem et al., 2017) . In another study examining cytokine concentrations and their relationship with suicidality, IL-6 levels were significantly elevated in the CNS of individuals who had attempted suicide compared to healthy controls (1.97 pg/mL vs. 0.64 pg/mL, respectively; p < .001) (Lindqvist et al., 2009 ). In the post-mortem brain tissue of teenagers who had completed suicide, the expression of both IL-6 and TNF-α was significantly increased compared to individuals without mental illness (p < .01) (Pandey et al., 2012) . Furthermore, other studies have found significant, positive relationships between symptoms of suicidality and CNS levels of IL-6 (β = 3.92; p = .04) (Bay-Richter et al., 2015) and systemic levels of TNF-α (β = 0.152; p = .025) (Eller et al., 2009 ). Considering these biologic findings, elevated levels of these inflammatory cytokines, which are typically seen in psoriasis, may play a role in the development of depression and SIB in psoriasis patients.
Although the overlap in cytokine profiles between depression and SIB suggests that the relationship between psoriasis and suicidality may be mediated through a pathway that includes depression, a pathway independent of depression may also exist. In a 2014 study by Pandey et al., the protein expression levels of multiple TLRs, which have been implicated in the formation and maintenance of psoriatic plaques and postulated to be a genetic component of the disease, were significantly increased in the brains of individuals who committed suicide, regardless of the presence of depression, when compared to healthy controls (Pandey et al., 2014) . Therefore, the inflammatory state of psoriasis may result in suicidality without the conduit of depression.
| Systemic psoriasis treatments and suicidality
Given the proposed biologic mechanisms linking psoriasis and SIB, it is reasonable to believe that immunomodulatory therapies targeting specific inflammatory mediators and cytokines may be helpful in managing not only the skin disease but also any associated suicidality.
Treatment with biologics, such as adalimumab, etanercept, infliximab, secukinumab, and ixekizumab, reduce the circulating levels of TNF-α and/or IL-17. However, cases of SIB have been reported in clinical trials and postmarketing surveillance with some of these anti-cytokine therapies (Gooderham et al., 2016; Marcus, 2016; Strober et al., 2018) . Most recently, the IL-17 receptor blocker, brodalumab, raised concerns due to observed SIB in clinical trials (Marcus, 2016) . Thus, as the potential link between biologics and suicidality has become of increasing clinical concern, recent literature has evaluated these associations.
In a recent study of the U. (Gupta, Pur, Vujcic, & Gupta, 2017) . Similarly, comprehensive review of the literature and analysis of the available data have also shown that immunomodulatory agents, including brodalumab, do not increase the risk of SIB in psoriasis patients (Chiricozzi, Romanelli, Saraceno, & Torres, 2016; Gooderham et al., 2016; Lebwohl et al., 2018) . Rather, treatment with biologics has been shown to improve mental health status and HRQoL and reduce SIB in patients with psoriasis when compared to placebo and/or conventional systemic therapies (Chiricozzi et al., 2016; Feldman et al., 2008; Gordon et al., 2014; Menter et al., 2010; Strober et al., 2018) . Additionally, even in patients without psoriasis, biologic agents have been found to be effective in treating psychiatric conditions (Raison et al., 2013) . In a randomized controlled trial of infliximab in treatment-resistant depression, treatment with infliximab substantially improved a wide range of depressive symptoms, including not only depressed mood, anhedonia, and fatigue but also, notably, suicidal ideation, in individuals with elevated inflammatory biomarkers at baseline (Raison et al., 2013) . Therefore, biologic agents may be a potential treatment for suicidality in psoriasis patients and warrant further exploration.
Interestingly, although biologics have not been associated with SIB more than other systemic medications, they have been associated with an increased risk of suicidality when used specifically in psoriasis compared to other diseases. In Gupta et al.'s 2017 study, the risk of completed suicide when biologics were used for psoriasis was significantly greater than that when biologics were used for any other indication (OR 1.47; 95% CI 1.03-2.11) (Gupta et al., 2017) . This suggests an inherent, increased risk of suicidality in psoriasis, as reported by several epidemiologic studies (Dalgard et al., 2015; Kurd et al., 2010; Pompili et al., 2016; Pompili et al., 2017; Singh et al., 2017; Zachariae et al., 2004) , independent of biologic therapy. Therefore, the observed incidences of SIB in psoriasis patients on biologics may ultimately reflect an underlying epiphenomenon.
| CONCLUSION
The relationship between psoriasis and SIB is complex and multi-faceted. The high incidence and prevalence of SI, suicide attempt, and completed suicide observed in the psoriasis population suggests that psoriasis may be an independent risk factor for suicidality. However, the available literature is limited and inconsistent, and the association between the two remains unclear, even with the addition of two recent meta-analyses. Although some may argue that depression mediates the relationship between psoriasis and suicidality, epidemiologic and biomolecular studies indicate that a pathway independent of depression may exist and suggest that an underlying inflammatory molecular mechanism may link psoriasis and suicidality. Furthermore, as the use of certain biologics for the treatment of psoriasis has recently posed questions regarding their safety and the risk of potential psychiatric adverse effects, studies suggest that the contribution of these agents on suicidality is minimal and that treatment with immunomodulatory therapies may actually improve SIB in patients with psoriasis. Although further investigation is needed, increasing awareness of the potential link between psoriasis and suicidality may help physicians more completely address the needs of psoriasis patients and, ultimately, prevent SIB in this population.
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